Table 2. Correlation of quantitative detection of CK20-mRNA and association to clinical characteristics determined by χ2 testing.
| CK20 ≥2.77 EU N (%) |
P | |
|---|---|---|
| all | 161 (42.3) | |
| age [years] | ||
| < 70 | 82 (39.0) | 0.097 |
| ≥ 70 | 79 (46.2) | |
| Sex | ||
| male | 92 (39.1) | 0.073 |
| female | 69 (47.3) | |
| tumour site | ||
| colon | 91 (40.6) | 0.253 |
| rectum | 70 (44.6) | |
| UICC stage | ||
| I | 42 (35.6) | <0.001 |
| II | 35 (38.5) | |
| III | 26 (29.9) | |
| IV | 58 (68.2) | |
| pT | ||
| T0 | 4 (50.0) | 0.004 |
| T1 | 8 (20.0) | |
| T2 | 38 (38.0) | |
| T3 | 83 (44.6) | |
| T4 | 28 (59.6) | |
| pN | ||
| N0 | 88 (39.1) | 0.083 |
| N+ | 73 (46.8) | |
| pM | ||
| M0 | 103 (34.8) | <0.001 |
| M1 | 58 (68.2) | |
| neoadjuvant treatment | ||
| yes | 24 (44.4) | 0.429 |
| no | 137 (42.1) | |
| adjuvant treatment | ||
| yes | 57 (41.9) | 0.460 |
| no | 104 (43.0) |
All P values in bold are regarded as statistically significant; CK20: cytokeratin 20; EU: expression units.